Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIq-ai Ltd Share News (IQAI)

Share Price Information for Iq-ai Ltd (IQAI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.55
Bid: 1.50
Ask: 1.60
Change: 0.00 (0.00%)
Spread: 0.10 (6.667%)
Open: 1.55
High: 1.55
Low: 1.55
Prev. Close: 1.55
IQAI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Zegona profit sinks; Flowtech Fluidpower suffers loss

Tue, 20th Apr 2021 12:08

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

Zegona Communications PLC - acquires businesses in European telecommunications, media and technology sector - Posts pretax profit of EUR14.0 million in 2020, falling 67% from EUR42.1 million in 2019. Finance income plummets to EUR3.8 million from EUR38.2 million. "The principal reason for the movement compared to 2019 was that 2019 included a EUR28 million gain on the investment in Euskaltel and EUR10 million dividend from Euskaltel before it was accounted for as an associate," explains Zegona. Investee Euskaltel is a telecommunications provider in the North of Spain. Zegona to pay 4.6p per share to shareholders for 2020, down 8.0% from 5.0p for 2019. Zegona is the leading shareholder in Euskaltel and has two board seats. Euskaltel "expects significant further growth in 2021, both in terms of customer numbers and revenue".

----------

Aquila European Renewables Income Fund PLC - renewable energy infrastructure investor - Reports net asset value per share at December 31 of 99.96 euro cents, down 2.7% from 102.7 cents a year prior. Net assets double to EUR316.9 million from EUR158.9 million. Declares dividend of 4.0 cents per share for 2020, up from 1.5 cents for 2019 and in line with its dividend target of 4.0 cents. Aims to increase dividend target to 5.0 cents per share in 2021. Says its investment strategy is unchanged, and it will continue to invest in renewable energy projects in Europe and the UK. Notes continuing uncertainty caused by Covid-19.

----------

RBG Holdings PLC - London-based law firm - Post pretax profit for 2020 of GBP7.7 million, up 1.3% from GBP7.6 million the year prior. Revenue increases 13% to GBP22.4 million from GBP19.9 million. Personnel costs increase to GBP17.9 million from GBP11.5 million. Pays dividend of 3 pence per share for year. "Based on current outlook, we expect to pay up to 60 per cent of retained earnings in the 2021 financial year by way of dividend," says RBG. "The business will benefit from life post-Brexit and post-Covid as businesses return to normality. Our litigation finance business, LionFish is now established, and we expect the number of cases it invests in to grow, with the first return expected in the first half. With a strong pipeline of deals, and increased interest in [mergers & acquisitions] in 2021, Convex Capital is expected to perform well," says RBG. Convex Capital is a specialist provider of sell-side only M&A advice to UK, US and European entrepreneurs.

----------

Flowtech Fluidpower PLC - Cheshire, England-based valves and hydraulic components maker - Posts pretax loss for 2020 of GBP2.1 million, swinging from a GBP4.7 million profit a year prior. Revenue falls 15% to GBP95.1 million from GBP112.4 million. "With hindsight, there are areas that we could have improved on, particularly around the pace with which we have been able to extract cost from our order, pick and drop activities, that will be essential to our future success...However, we end 2020 having made progress in creating the platform that will ensure our future growth," says Flowtech. Does not declare dividend, but says it remains "keen to reintroduce a final payment for the financial year 2021, and thereafter adopt a balanced approach to dividend policy". "We have been encouraged by our performance over the past quarter, with both revenue and margins trending slightly above our expectations. The combination of Brexit and Covid-19, and in particular the current challenged nature of global supply chains, continue to make underlying trading difficult to interpret. What is clear is there has been a continued upward trend in our 'resellers' business, and evidence of restocking in our OEM customers," says Flowtech. Says if current trading continue, company could exit 2021 with similar revenue to 2019.

----------

MaxCyte Inc - Maryland-based cell and gene therapies firm - Posts net loss of USD11.8 million in 2020, narrowing 8.5% from USD12.9 million the year prior. Revenue increases 21% to USD26.2 million from USD21.6 million. Says it has never declared or paid common stock dividends and has no plans to do so in the foreseeable future. "We expect strong revenue growth in 2021, driven by the continuing progress of our existing strategic partners into and through the clinic and subsequent generation of increased milestone revenues. We are also confident that throughout the coming year we will continue to build our customer base and continue to secure further high-value licensing agreements, driving ongoing growth. The strategic partnership pipeline coming into 2021 is the largest that the company has experienced to date," says MaxCyte.

----------

discoverIE Group PLC - Guildford-based designer, manufacturer and supplier of customised electronics - Says trading momentum in the final two months of the year, to March 31, has continued to strengthen, and the company now expects underlying earnings for the full year to be above the upper end of market expectations. Says sales in the second half were 9% ahead of the first half with a return to organic growth of 1% in the last two months of the year. Sales for the full year were 3% lower, down 6% organically. "The strong order book and momentum provide a solid base for sustained organic sales growth whilst further investing in growth initiatives," says company.

----------

Filta Group Holdings PLC - AIM-listed provider of fryer management - Swings to pretax loss of GBP866,231 in 2020 from a GBP936,284 profit a year prior. Revenue falls 34% to GBP16.4 million from GBP24.9 million. Does not declare a final dividend, compared to 1.0p per share a year before. Says that "provided the progress that has been made in the first quarter of the year continues, it fully expects to be able to resume the payment of dividends in respect of 2021". Says that the upward trend in business levels that the company saw in the second half of 2020 has continued into the current year, with the numbers of new customers in both of its markets, the UK and North America, being particularly encouraging. "With the lockdown restrictions expected to be lifted further over the next two to three months and with the vaccination programmes progressing well in the UK and US, the board is confident that the progress that we have seen in the first quarter will continue through the year and, moreover, that the group is emerging from a highly challenging time much stronger operationally and in robust financial health," says Filta.

----------

IQ-AI Ltd - medical software company with headquarters in Jersey - Posts pretax loss for 2020 of GBP717,534, widening from GBP638,654 in 2019. Administrative expenses increase 5.4% to GBP933,462 from GBP885,757. Revenue falls 6.4% to GBP255,314 from GBP272,867. Declares no dividend for 2020, unchanged from 2019. Says the top priority going forward is to "increase in sales and distribution of its advanced imaging solutions".

----------

J Smart & Co (Contractors) PLC - Edinburgh-based construction contractor - Posts pretax profit for the first half to end-January of GBP890,000, widening from GBP265,000 a year before. Revenue falls 38% to GBP5.8 million from GBP9.3 million. Cost of sales halve to GBP5.3 million from GBP10.0 million. Announces an interim dividend of 0.95p per share, flat with the year prior. "We have substantially less work in hand in contracting than the same time last year. It is by no means certain that new contracting work will be secured this financial year due to general delays caused by the coronavirus pandemic," says J Smart. Says it is difficult to give accurate guidance due to uncertainties, but the company does not expect underlying profit to increase this financial year.

----------

By Greg Roxburgh; gregroxburgh@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
22 Feb 2024 14:02

IN BRIEF: IQ-AI shares sink on discounted placing fundraise

IQ-AI Ltd - Medical services firm and parent company of Wisconsin-based healthcare imaging software firm Imaging Biometrics LLC - Announces placing to raise GBP300,000 gross proceeds via the issue of 20.0 million new shares at a price of 1.5p each. The issue price represents a discount of 32% to the company's Wednesday closing price of 2.2p. The placing includes a broker option for existing shareholders for up to 6.7 million new shares, which would raise an additional GBP100,000. Admission of the new placing and broker option shares is expected to occur on or around March 1.

Read more
9 Feb 2024 13:38

IQ-AI subsidiary asked by FDA to resubmit and modify application

(Alliance News) - IQ-AI Ltd on Friday said its subsidiary Imaging Biometric LLC will modify and resubmit its application to the US Food & Drug Administration.

Read more
2 Feb 2024 08:56

IN BRIEF: IQ-AI celebrates USD100,000 grant for subsidiary

IQ-AI Ltd - St Helier, Jersey-based medical services firm - Says that Imaging Biometrics LLC, a wholly-owned subsidiary of IQ-AI, has been given a USD100,000 grant by the Musella Foundation For Brain Tumor Research & Information Inc. Explains that the grant will help to support the launch of an intermediate group expanded access programme, which is focused on giving brain tumour patients access to oral gallium maltolate, outside of an ongoing Phase One clinical trial at the Medical College of Wisconsin. The grant will be used to facilitate the expanded access programme, including writing and submitting the study protocol, patient screening and on-boarding.

Read more
10 Jan 2024 11:48

IQ-AI falls after subsidiary notes launch of treatment access scheme

(Alliance News) - IQ-AI Ltd shares fell on Wednesday, after it said its subsidiary Imaging Biometrics LLC is launching an intermediate population cohort expanded access programme for oral gallium maltolate.

Read more
19 Dec 2023 17:00

IQ-AI firm gets US FDA fast-track status for oral gallium maltolate

(Alliance News) - IQ-AI Ltd on Tuesday said the US Food & Drug Administration has granted 'fast-track" designation for oral gallium maltolate, which is its subsidiary Imaging Biometrics LLC's therapeutic for the treatment of adult patients with relapsed or refractory glioblastoma.

Read more
5 Dec 2023 11:49

IQ-AI stock rises on positive interim results from glioblastoma trial

(Alliance News) - IQ-AI Ltd on Tuesday reported positive results from Phase 1 of an on-going study for its investigational monotherapy oral gallium maltolate.

Read more
8 Nov 2023 12:04

IQ-AI says Imaging Biometrics submits paediatric rare disease request

(Alliance News) - IQ-AI Ltd on Wednesday said its wholly-owned subsidiary Imaging Biometrics LLC has submitted a paediatric rare disease request to the US Food & Drug Administration for its gallium maltolate therapy.

Read more
18 Oct 2023 17:11

IN BRIEF: IQ-AI subsidiary "central" to "landmark" brain cancer study

IQ-AI Ltd - St Helier, Jersey-based medical services firm focused on cancer treatment - Notes its wholly-owned subsidiary, Imaging Biometrics LLC (IB), has announced the results of a "landmark" study. Says the study represents the first large-scale characterization of the invasive tumour margins of high-grade glioma using multi-regional genomic/transcriptomic sequencing with spatially matched MRI measurements in glioma. High-grade glioma is a deadly brain cancer. Explains that Imaging Biometrics' IB Neuro's dynamic susceptibility contrast magnetic resonance imaging software was central to the study.

Read more
9 Oct 2023 12:09

IN BRIEF: IQ-AI subsidiary wins orphan drug designation from US FDA

IQ-AI Ltd - St Helier, Jersey-based medical services firm focused on cancer treatment - Wholly-owned subsidiary Imaging Biometrics LLC is granted an orphan drug designation from the US Food & Drug Administration for gallium maltolate for the treatment of atypical teratoid rhabdoid tumour. Notes this is the second orphan designation granted to gallium maltolate this year.

Read more
8 Sep 2023 10:25

IQ-AI notes vindication of subsidiary's reduced gadolinium approach

(Alliance News) - IQ-AI Ltd on Friday noted that studies by its subsidiary Imaging Biometrics LLC validated the dosing approach of Imaging's MRI-focused IB Neuro.

Read more
18 Aug 2023 12:17

IQ-AI shares jump on subsidiary's GE Healthcare deal

(Alliance News) - IQ-AI Ltd on Friday said its wholly-owned subsidiary Imaging Biometrics LLC has signed a deal with GE HealthCare Technologies Inc.

Read more
17 Aug 2023 11:21

IQ-AI interim loss narrows amid higher revenue, lower expenses

(Alliance News) - IQ-AI Ltd on Thursday announced a slightly lower loss for the six months to June 30, as revenue was up and administrative expenses were lower.

Read more
19 Jul 2023 10:45

IN BRIEF: IQ-AI subsidiary's app adopted by US medical college

IQ-AI Ltd - Jersey-based medical services firm focused on cancer treatment - Says subsidiary Imaging Biometrics LLC's handheld application IB Nimble has been adopted by the Medical College of Wisconsin's Orthopedic Department for use in bone metastases treatment. IB Nimble's designer, Joseph Bovi, is professor of radiation oncology & neurosurgery at MCW. The application was originally designed to help treat brain metastases. IQ-AI says it "provides real-time collaboration amongst multi-disciplinary teams" to "provide optimised treatments faster". Josh McComack, Imaging Biometrics' director of software engineering, says the new installation "demonstrates that IB Nimble is ready for widespread deployment."

Read more
13 Jul 2023 11:36

IN BRIEF: IQ-AI granted orphan drug designation for Gallium Galtolate

IQ-AI Ltd on Thursday - Jersey-based incubator of software and other tools for the treatment of cancer - IQ-AI subsidiary Imaging Biometrics LLC has been granted an orphan drug designation for Gallium Galtolate for the treatment of paediatric glioblastoma multiforme, or GBM, by the US Food & Drug Administration. Says GBM is the most common and aggressive primary brain tumour in adults and children. Imaging Biometrics' application to the FDA was first submitted in April. In June, two pre-clinical studies showed oral GaM inhibits brain tumour growth in children, and the results were consistent with previous work conducted in the Schmainda Lab at the Medical College of Wisconsin.

Read more
27 Jun 2023 11:47

IN BRIEF: IQ-AI notes Gallium Moltate studies on tumour growth

IQ-AI Ltd - Jersey-based medical services firm - Says subsidiary Imaging Biometrics LLC's two new pre-clinical studies show oral Gallium Maltolate inhibits brain tumour growth in children. Says the results are consistent with previous work conducted in the Schmainda Lab at the Medical College of Wisconsin. This follows IB's application for Orphan Drug Designation to the US Food & Drug Administration back in April for the use of GaM in pediatric brain tumours. Notes application is currently under review.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.